MHRA Alert – IXCHIQ Chikungunya Vaccine Temporarily Restricted in Adults Aged 65+

Temporary Suspension Notice

The Commission on Human Medicines (CHM) has temporarily restricted the use of IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare but serious adverse events reported globally. This is a precautionary measure to allow further investigation.

Key Points

• IXCHIQ should not be administered to patients aged 65 years or older until further notice
• Very rare fatal reactions have been reported internationally
• This restriction applies only to the older age group; use in younger adults continues under standard risk–benefit assessment
• The CHM is actively monitoring emerging safety data

Affected Medication

• IXCHIQ (Chikungunya vaccine)

Recommended Actions

• Review patient records for any scheduled IXCHIQ vaccinations in patients aged 65+
• Postpone or cancel these appointments until further guidance is issued
• Inform affected patients of the temporary suspension and the reason
• Stay alert for further updates from the MHRA and CHM
• Report any suspected adverse reactions via the Yellow Card scheme

Further Information

For the full MHRA drug safety update, visit the official MHRA guidance.